Patents Assigned to Institute of Materia Medica, Chinese Academy of Medical Sciences
  • Publication number: 20200181115
    Abstract: Provided is a method for preparing 2-hydroxy-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative represented by formula (I). The method comprises the following steps: (1) preparing 3-aryl-2-substituted toluene derivative 2 by using 3-iodo-2-substituted toluene derivative 1 and aryl boronic acid 5 or aryl boronate as starting materials; (2) preparing a benzyl halide derivative 3 by using 3-aryl-2-substituted toluene derivative 2 as starting materials; and (3) preparing 4-(2, 3-disubstituted benzyloxy)-2-hydroxy-5-substituted benzaldehyde derivative (I) by using benzyl halide derivative 3 and 2,4-dihydroxy-5-substituted benzaldehyde 6.
    Type: Application
    Filed: May 23, 2017
    Publication date: June 11, 2020
    Applicant: Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Zhiqiang Feng, Xiaoguang Chen, Yang Yang, Fangfang Lai
  • Patent number: 10611852
    Abstract: Provided are an insulin-lipid complex, a preparation method thereof, and a formulation thereof. The insulin-lipid complex is prepared by compounding insulin and a lipid material in an organic solvent system containing a low boiling point acid, and drying. The mass ratio of insulin to the lipid material is 1:3˜1:20. An oil solution of the insulin-lipid complex and vesicles containing insulin are further provided.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: April 7, 2020
    Assignee: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Yuling Liu, Cuiping Zhou, Zhihui Song, Lin Li, Hongliang Wang, Xuejun Xia, Renyun Wang, Wujun Dong, Dujia Jin
  • Publication number: 20200055819
    Abstract: The present invention discloses a nicotinyl alcohol ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to nicotinyl alcohol ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.
    Type: Application
    Filed: May 23, 2017
    Publication date: February 20, 2020
    Applicants: Institute of Materia Medica, Chinese Academy of Medical Sciences, Tianjin Chase Sun Pharmaceutical Co., LTD
    Inventors: Zhiqiang Feng, Xiaoguang Chen, Yang Yang, Yi Zheng, Fangfang Lai, Ming Ji, Chuan Zhou, Lijing Zhang, Ke Wang, Nina Xue, Ling Li
  • Patent number: 10174033
    Abstract: The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: January 8, 2019
    Assignee: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Jiangong Shi, Jianjun Zhang, Zhenggang Yue, Min Li, Chenggen Zhu, Ying Zhang, Jiachen Zi, Yafang Wang, Xiaona Fan, Ruiming Xu, Sheng Lin, Yan Li, Yongchun Yang, Li Sheng
  • Patent number: 9393277
    Abstract: The present invention discloses an Albizzia chinensis extract used in the preparation of a drug for the treatment of gastric ulcers. Specifically, it discloses an Albizzia chinensis (Osbeck) Merr extract and its preparation method including the stems bark of Albizzia chinensis was successively grounded, extracted, concentrated and purificated, as well as a pharmaceutical composition comprising the Albizzia chinensis extract. Through pharmacological test, it has been demonstrated that, the Albizzia chinensis extract showed strong inhibition activity against proton pumps, and it can be used for the treatment of gastric ulcers, chronic gastritis and other acid-related diseases, and its anti-ulcer effect is significant, quick, safe and reliable.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: July 19, 2016
    Assignee: Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Shishan Yu, Jianjun Zhang, Shuanggang Ma, Ruiming Xu, Chengxue Ji
  • Patent number: 9266897
    Abstract: Disclosed are derivatives of protoberberine biological alkaloids or physiologically acceptable salts thereof produced by means of a derivative reaction of a source material of biological alkaline quaternary ammonium salts of protoberberine alkaloids, a preparation method for same and pharmaceutical uses thereof. The derivatives of protoberberine biological alkaloids or the physiologically acceptable salts thereof show activity inhibiting ulcerative colitis and can be used in the preparation of drugs for same.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: February 23, 2016
    Assignee: Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Hailin Qin, Wenjie Wang, Zhihui Zhang, Lianqiu Wu, Anjun Deng, Jinqian Yu, Zhihong Li
  • Patent number: 9206405
    Abstract: A novel glycosyl hydrolase with activities of beta-xylosidase and beta-glucosidase is provided. Said glycosyl hydrolase can convert 7-xylosyltaxane compounds to 7-hydroxyltaxane compounds.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: December 8, 2015
    Assignee: Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Ping Zhu, Haili Cheng, Ruiyu Zhao, Kedi Cheng, Huixia He, Chao Meng, Huixin Zhu
  • Publication number: 20150031717
    Abstract: Disclosed are derivatives of protoberberine biological alkaloids or physiologically acceptable salts thereof produced by means of a derivative reaction of a source material of biological alkaline quaternary ammonium salts of protoberberine alkaloids, a preparation method for same and pharmaceutical uses thereof. The derivatives of protoberberine biological alkaloids or the physiologically acceptable salts thereof show activity inhibiting ulcerative colitis and can be used in the preparation of drugs for same.
    Type: Application
    Filed: October 24, 2012
    Publication date: January 29, 2015
    Applicant: Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Hailin Qin, Wenjie Wang, Zhihui Zhang, Lianqiu Wu, Anjun Deng, Jinqian Yu, Zhihong Li
  • Publication number: 20140323501
    Abstract: Immune-modulators of formula (I) below are prepared: A pharmaceutical composition contains the immune-modulators. The pharmaceutical composition is used as a drug, especially as an immune-modulating drug. The compound can be used in treatment of immune disorders and for immune suppression. Thus, for example, the compound can be used in treating hypo-immunity, rejection after organ transplantation and auto-immune disease.
    Type: Application
    Filed: July 5, 2012
    Publication date: October 30, 2014
    Applicant: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Weijuan Han, Haijing Zhang, Xiaojian Wang, Jing Jin, Gang Li, Yi Zhang, Qiong Xiao, Wanqi Zhou, Xiaoguang Chen, Dali Yin
  • Patent number: 8765695
    Abstract: The present invention relates to use of an active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt for preparing a medicament and a health care product for improving sexual function of male mammals, and for providing the effect of spermatogenesis. The present invention further relates to a pharmaceutical composition for improving sexual function of male mammals, and/or for providing the effect of spermatogenesis, which comprises at least one active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt, and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: December 25, 2007
    Date of Patent: July 1, 2014
    Assignees: Jecui Health Industry Corp. Ltd., Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Juntian Zhang, Shifeng Chu
  • Publication number: 20130338064
    Abstract: Provided are an insulin-lipid complex, a preparation method thereof, and a formulation thereof. The insulin-lipid complex is prepared by compounding insulin and a lipid material in an organic solvent system containing a low boiling point acid, and drying. The mass ratio of insulin to the lipid material is 1:3˜1:20. An oil solution of the insulin-lipid complex and vesicles containing insulin are further provided.
    Type: Application
    Filed: July 14, 2011
    Publication date: December 19, 2013
    Applicant: Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Yuling Liu, Cuiping Zhou, Zhihui Song, Lin Li, Hongliang Wang, Xuejun Xia, Renyun Wang, Wujun Dong, Dujia Jin
  • Patent number: 8399511
    Abstract: Two crystalline forms of pinocembrin of formula (I): ? and ?, their preparation and their use for manufacture of pharmaceutical compositions. There exists difference between them in bioavailability. They are used for treating and preventing cerebral ischemic diseases by protective action of neurovascular unit, and enhancing blood drug level in vivo.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: March 19, 2013
    Assignees: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Guanhua Du, Yang Lv, Song Wu, Ke Wang, Ying Chang, Zhihong Yang, Yuanfeng Tong, Mei Gao
  • Patent number: 8399691
    Abstract: The present invention relates to a method for resolution of a mixture of pinocembrin optical isomers, in particular a pinocembrin racemate, using a chiral primary amine or a chiral sulfinamide. The present invention also relates to a (R)-(+)-pinocembrin obtained by the method.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: March 19, 2013
    Assignees: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd., Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Song Wu, Guanhua Du, Yue Yuan, Qingyun Yang, Mei Gao, Yan Qi, Yuanfeng Tong, Yuehua Wang
  • Publication number: 20130045942
    Abstract: The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.
    Type: Application
    Filed: December 10, 2009
    Publication date: February 21, 2013
    Applicant: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Jiangong Shi, Jianjun Zhang, Zhenggang Yue, Min Li, Chenggen Zhu, Ying Zhang, Jiachen Zi, Yafang Wang, Xiaona Fan, Ruiming Xu, Sheng Lin, Yan Li, Yongchun Yang, Li Sheng
  • Patent number: 8338401
    Abstract: The present invention relates to novel coumarin derivatives, their carboxamides, pharmaceutical compositions containing them and their uses as drugs for kidney protection, treating drugs of hypertension, cardio-cerebrovascular diseases, non-insulin dependent diabetes, tumor, pre-cancerous lesion, and edemas.
    Type: Grant
    Filed: December 5, 2003
    Date of Patent: December 25, 2012
    Assignee: Institute of Materia Medica Chinese Academy of Medical Sciences
    Inventors: Shiping Xu, Xiaoguang Chen, Song Xu, Lanmin Li, Longfei Xie, Hongyan Li, Yan Li, Guifang Cheng
  • Publication number: 20110130352
    Abstract: The present invention relates to an effective fraction of alkaloids and the effective fraction is prepared from mulberry twig and its active ingredients are a composition of alkaloids. Determined by HPLC, the percentage of the total alkaloids are 50% or more by weight in the effective fraction and the percentage of the compound 1-deoxynojirimycin is 30% or more by weight in the total alkaloids. The effective fraction of the invention is prepared as the following steps: the mulberry twig is extracted by solvents, and the extract is precipitated by alcohol precipitation or flocculation to remove the impurities, and then concentrated, purified by resin chromatography. The present invention also relates to a pharmaceutical composition containing the said effective fraction of alkaloids and to the use of the effective fraction of alkaloids according to claim 1-4 in preparing hypoglycemic agents.
    Type: Application
    Filed: August 22, 2007
    Publication date: June 2, 2011
    Applicant: Institute of Materia Medica Chinese Academy of Medical Sciences
    Inventors: Yuling Liu, Zhufang Shen, Zhen Chen, Renyun Wang, Xuejun Xia, Yueteng Chen, Quan Liu, Sujuan Sun, Mingzhi Xie
  • Publication number: 20110034403
    Abstract: The present invention relates to use of an active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt for preparing a medicament and a health care product for improving sexual function of male mammals, and for providing the effect of spermatogenesis. The present invention further relates to a pharmaceutical composition for improving sexual function of male mammals, and/or for providing the effect of spermatogenesis, which comprises at least one active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt, and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: December 25, 2007
    Publication date: February 10, 2011
    Applicant: INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Juntian Zhang, Shifeng Chu
  • Patent number: 7557089
    Abstract: The use of extract form Wangla (coeloglossum viride (L) Hartm. Var. Bracteatum (Willd.) Richter), succinate derivative esters, and a derivative and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for the treatment of dementia, particularly for the treatment of Alzheimer' disease and Vascular dementia. Through Animal experiment, it has been demonstrated that, succinate derivative esters can improve learning and memory ability in dementia rats induced by scopolamine and cyclohexenyl imine; improve learning and memory ability in dementia rats induced by ?-amyloid; improve learning and memory ability in dementia rats induced by permanent ligation of bilateral carotid; and improve memory ability of normal animals. It has the advantage of high activity, low toxicity and no inhibition to cholinesterase.
    Type: Grant
    Filed: December 31, 2003
    Date of Patent: July 7, 2009
    Assignee: Institute of Materia Medica, Chinese Academy of Medical Science
    Inventors: Jianjun Zhang, Jiangong Shi, Yafang Wang, Dan Zhang, Mei Gao, Yongchun Yang, Shengyang Huang
  • Patent number: 7550507
    Abstract: The invention relates to new synthetic 2-(?-hydroxypentyl) benzoates, their preparation and pharmaceutical compositions containing such salts as active ingredients. The invention also relates to the use of the compounds for preventing and treating cardioischemia, cerebroischemia and cardiac or cerebral arterial occlusion (obstruction), etc.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: June 23, 2009
    Assignee: Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Jinghua Yang, Xiaoliang Wang, Zhibin Xu, Ying Peng
  • Patent number: 6787564
    Abstract: The present invention relates to some new optically active clausenamide derivatives, process of the preparation thereof, a pharmaceutical composition containing the same and their medical use, particularly their use in the respects of hypoxia protective, nootropic and neurodegenerative disease such as cerebral ischemia, Alzheimer disease and vascular dementia.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: September 7, 2004
    Assignee: Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Juntian Zhang, Liang Huang, Kemei Wu, Shiming Chen